Financial Data and Key Metrics Changes - Q4 2025 revenue increased by 32% compared to Q3 2025, approaching the revenue level of the prior year quarter despite a significantly reduced team [6] - Full year pro forma cash basis EBITDA improved by 31% compared to 2024, with a 56% improvement in Q4 alone [6] - Gross margin for the year improved to 40%, up from 38% in 2024 [7] - Net operating results for 2025 improved by 23%, while GAAP net loss for Q4 2025 was impacted by one-time accounting-related charges totaling $6.3 million [7] Business Line Data and Key Metrics Changes - The revenue mix has diversified, reducing reliance on a single platform, with revenue now more balanced across Roblox, Minecraft, Fortnite, and mobile playable ads [8] - Mobile playables accounted for over 25% of revenue in Q4 2025, ending the year at about 20% [32] - Revenue from Roblox diminished to under 40% of total revenue, while Fortnite and Minecraft collectively contributed about 30% [32] Market Data and Key Metrics Changes - The U.S. digital advertising market is valued at $316 billion, with a gaming population of 200 million, yet total yearly spend in gaming remains under $10 billion [9][10] - Consumers spend approximately 11.8 hours per week playing video games, nearly equal to time spent on social media and streaming [9] Company Strategy and Development Direction - The company aims to maintain a lower cost structure while expanding scalable, repeatable revenue streams [14] - The acquisition of the Misfits Ads Division is expected to enhance revenue capabilities and contribute significantly to cash basis EBITDA profitability [11][21] - The strategy focuses on leveraging audience intelligence to drive scale and profitability, with an emphasis on understanding consumer behavior through gameplay-derived signals [10][11] Management's Comments on Operating Environment and Future Outlook - Management expects Q1 2026 revenue to exceed Q1 2025, with a consistent pipeline and average deal size above $200K [12] - The full financial impact of recent changes is not yet reflected in reported results, but meaningful progress is anticipated starting in Q2 2026 [12] - The company is optimistic about long-term potential in digital assets and is actively evaluating opportunities in this area [13][14] Other Important Information - The company has a debt-free balance sheet with over $14 million in capital as of December 31, 2025 [4] - The strategic deals completed in 2026 are expected to create a cohesive operating model that reinforces growth [9] Q&A Session Summary Question: Progression towards cash-based EBITDA profitability in 2026 - Management outlined a three-phase approach for 2026, expecting Q1 to show some lag, Q2 to reflect a visible inflection, and the second half to focus on delivery [16][17] Question: Details on the Misfits acquisition and its impact - The acquisition is expected to consolidate complementary businesses and provide access to a profitable revenue stream, potentially contributing 50% of 2025 net revenue [21][22] Question: Sustainability of gross margin improvements - Management indicated that gross margins are expected to return above 40% in Q2, with a focus on maintaining healthy margins despite seasonal pressures [24][39]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $8.4 million, down from $14.6 million in Q4 2024, primarily due to government shutdown impacts [25] - Product revenues decreased to $5.6 million from $12.6 million year-over-year, attributed to delays in product orders and shipments for U.S. Defense applications [25] - Non-product revenues increased to $2.5 million from $1.7 million, driven by the IVAS color microLED development program [26] - Cost of product revenue was $4.7 million, representing 83% of net product revenues, compared to $10.7 million or 84% in the previous year [27] Business Line Data and Key Metrics Changes - The defense programs remain the core of the business and the strongest growth driver, with ongoing supply for thermal weapon sight programs [12] - The company has seen increased demand for its products due to geopolitical conflicts, indicating a strong recovery potential [5] - The partnership with THEON International has opened new revenue opportunities in European and NATO defense markets, with sales commencing and expected to grow significantly [10] Market Data and Key Metrics Changes - Increased defense budgets across NATO member states are driving growth expectations, particularly in Europe, with three new contracts announced in Q1 2026 [10] - The U.S. drone market is projected to grow significantly, with the first-person drone market expected to increase from under $300 million to $1.2 billion by 2030, a 31% compound annual growth rate [11] Company Strategy and Development Direction - The company is transitioning from a legacy microdisplay company to a vertically integrated advanced technology platform, focusing on strategic partnerships and global expansion [4][7] - The second phase of the transformation plan emphasizes acceleration, expansion, and innovation, aiming for sustainable growth and profitability [21][22] - The company is positioned to capture opportunities in defense and other applications, leveraging its unique manufacturing capabilities in microdisplays [18] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the government shutdown as a temporary setback, emphasizing a strong balance sheet and a robust defense pipeline [31] - The company expects a conservative revenue guidance of $52 million to $60 million for 2026, anticipating recovery as government operations normalize [22] - Management is optimistic about the company's potential for meaningful growth in 2026 and beyond, driven by strategic initiatives and partnerships [19][32] Other Important Information - The company raised $56 million in capital from strategic and institutional investors, strengthening its financial foundation [4][30] - Automation investments are expected to deliver over $1 million in annual operating expense savings as they reach full utilization [17] Q&A Session Summary Question: What is the backlog as of December 31st? - Backlogs were approximately $37 million, with expectations to book larger orders soon [38] Question: Will the microLED program completion be delayed into 2027? - The company is working towards completion this year, with technical milestones on track [41] Question: How should capacity needs be viewed for the SBMC program? - The company has selected tooling equipment for production and does not require further CapEx to meet current program demands [46] Question: What is the outlook for the commercial open-market opportunity in the U.S. for drones? - There is surging demand for first-person viewers due to the FCC's DJI ban, with significant orders expected [52][53] Question: What is the expected allocation from the $450 billion reconciliation bill for microdisplays and optics? - The company is actively seeking additional funding and is optimistic about the budget's potential impact on defense systems [54][56] Question: Are there new markets and technologies outside the defense industry? - The company plans to announce two new products in new markets this year, indicating significant developments [59]

Financial Data and Key Metrics Changes - In 2025, Autolus recognized $74.3 million in revenue from AUCATZYL, with Q4 2025 net product revenue at $23.3 million [5][36] - The company expects net revenue for 2026 to be between $120 million and $135 million, with a shift to positive gross margins anticipated [5][46] - The net loss for Q4 2025 was $90.3 million, compared to $27.6 million for the same period in 2024 [39] Business Line Data and Key Metrics Changes - AUCATZYL's launch in the U.S. has been successful, with 67 centers activated by the end of 2025, and plans to increase to over 80 centers by the end of 2026 [5][6] - The company achieved regulatory approvals in the EU and U.K. by the end of 2025, initiating the launch in the U.K. at the beginning of 2026 [6] Market Data and Key Metrics Changes - The ROCCA consortium reported that 91 out of 96 patients treated with Obe-cel received infusions, with a 92% overall complete remission rate observed in the real-world setting [6][11] - The patient population treated showed a median age of about 50 years, with a wide range of age representation [8] Company Strategy and Development Direction - The company aims to broaden the utility of Obe-cel across additional indications, including pediatric patients and autoimmune diseases [14][15] - Autolus is focusing on expanding its commercial footprint and improving operational efficiencies to drive down costs and enhance gross margins [5][88] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing commercial launch of AUCATZYL and the positive feedback from physicians [5] - The company is evaluating market access in Europe and is cautious about entering markets in a financially sustainable manner [54] Other Important Information - The company recorded a $1 million license revenue component in Q4 2025 related to a clinical milestone with Moderna [36] - Cash equivalents and marketable securities totaled $300.7 million at the end of 2025, down from $588 million at the end of 2024 [39][45] Q&A Session Summary Question: Guidance for 2026 revenue from U.K. and other regions - Management indicated that the 2026 guidance includes both U.S. and U.K. markets but will not break out specific contributions due to early launch stages [52][53] Question: Insights on LUMINA enrollment - Enrollment for the LUMINA study is gaining momentum, with U.S. centers expected to come online soon [63] Question: Impact of ROCKA results on physician behavior - Management believes the ROCKA data will help build confidence among physicians, which is crucial for market share growth [58][60] Question: Early data disclosure for ongoing studies - Management stated that they do not plan to disclose early data from ongoing studies like BOBCAT and LUMINA to maintain the integrity of the trials [72][76] Question: Evolution of gross margin post-positive shift - Management explained that increasing patient volume and optimizing the operating model will drive down production costs and improve gross margins [86][88]

Financial Data and Key Metrics Changes - Q4 2025 revenue increased by 32% compared to Q3 2025, approaching the prior year quarter's revenue level despite a significantly reduced team [6][8] - Full year gross margin improved to 40%, up from 38% in 2024, reflecting a more disciplined approach to program delivery [8] - Pro forma cash basis EBITDA improved by 31% compared to 2024, with a 56% improvement in Q4 alone [7][8] - Cash basis pro forma OPEX costs decreased by 29% year over year, reflecting strategic cost reduction efforts [7] Business Line Data and Key Metrics Changes - Revenue mix has diversified, reducing reliance on a single platform; mobile playable ads accounted for over 25% of Q4 revenue, with Roblox revenue dropping to under 40% [33] - Growth in revenue from Fortnite and Minecraft collectively reached about 30% [33] Market Data and Key Metrics Changes - The U.S. digital advertising market is valued at $316 billion, with a gaming population of 200 million, yet total yearly spend in gaming remains under $10 billion, indicating a significant opportunity for growth [10] - Consumers spend approximately 11.8 hours per week playing video games, nearly equal to time spent on social media and television [10] Company Strategy and Development Direction - The company aims to maintain a lower cost structure while expanding scalable, repeatable revenue streams [15] - The acquisition of the Misfits Ads Division is expected to enhance revenue capabilities and contribute to cash basis EBITDA profitability [12][22] - The strategy focuses on leveraging data-driven insights to design effective campaigns across the digital landscape [11] Management's Comments on Operating Environment and Future Outlook - Management expects Q2 2026 to show more visible benefits from the transformation efforts initiated in 2025, with cash basis EBITDA profitability within reach by year-end [9][13] - The company is optimistic about the long-term potential of digital assets and is evaluating opportunities in this area [14] Other Important Information - The company has a debt-free balance sheet with over $14 million in capital as of December 31, 2025, and has removed going concern language from the auditor's report [4] - The company is actively integrating the Misfits Ads Division to leverage its capabilities and enhance revenue [44][46] Q&A Session Summary Question: Progression towards cash-based EBITDA profitability in 2026 - Management outlined a three-phase approach for 2026, expecting Q1 to show some lag, Q2 to reflect a visible inflection, and the second half to focus on delivery [17][19] Question: Details on the Misfits acquisition and its impact - The acquisition is expected to consolidate complementary businesses and enhance revenue, with anticipated net revenue contribution equal to approximately 50% of 2025's net revenue [22][23] Question: Gross margin sustainability and progression - Management indicated that gross margins are expected to return above 40% in Q2, with a focus on maintaining healthy margins throughout the year [25][40] Question: Growth in mobile gaming revenue - Mobile gaming revenue grew to over 25% in Q4, with expectations for further diversification in 2026, including potential expansion into connected TV and web gaming [33][35] Question: Acquisition strategy and future opportunities - The company plans to focus on integrating the Misfits Ads Division while remaining open to future M&A opportunities once the current acquisition proves successful [45][46]

Financial Data and Key Metrics Changes - In 2025, the company recognized $74.3 million in revenue from AUCATZYL, with a net product revenue of $23.3 million for Q4 2025 [5][34] - The total revenue for Q4 2025, including a $1 million license revenue component, was $24.3 million [35] - Cost of sales for Q4 2025 was $25.3 million, significantly higher than $11.4 million in Q4 2024, primarily due to a full quarter of sales and increased manufacturing expenses [36] - The net loss for Q4 2025 was $90.3 million, compared to $27.6 million in Q4 2024 [38] Business Line Data and Key Metrics Changes - The company achieved regulatory approvals in the EU and the U.K. by the end of 2025, initiating the launch of AUCATZYL in the U.K. at the beginning of 2026 [6] - The ROCCA consortium reported that 91 out of 96 patients treated with obe-cel received infusions, with a 92% overall complete remission rate observed in the real-world setting [11][12] Market Data and Key Metrics Changes - The company is targeting more than 80 activated centers by the end of 2026, building on the 67 centers activated by the end of 2025 [5] - The company does not expect significant contributions from the U.K. or other EU countries in 2026, focusing instead on the U.S. market [52][53] Company Strategy and Development Direction - The company aims to broaden the utility of AUCATZYL across additional indications, including pediatric patients and autoimmune diseases [15][17] - The focus for 2026 includes driving market share for AUCATZYL, improving gross margins, and expanding clinical trial programs [48] Management's Comments on Operating Environment and Future Outlook - Management reiterated guidance for 2026, expecting net revenue of $120 million to $135 million and a shift to positive gross margins [5][43] - The company is evaluating market access strategies in Europe to ensure economically sensible entry [53] Other Important Information - The company has a strong foundation in the adult ALL segment and is actively pursuing additional studies, including the CATULUS study for pediatric patients and the LUMINA study for lupus nephritis [14][30] - The company expects to have sufficient cash equivalents and marketable securities to fund operations into Q4 2027 [44] Q&A Session Summary Question: Guidance for 2026 revenue from U.K. and other regions - Management indicated that the guidance includes both U.S. and U.K. markets but will not break out specific contributions due to early launch stages [51][52] Question: Insights on ROCCA results and physician behavior - Management expressed confidence that the ROCCA data will enhance physician confidence and experience, which is crucial for market share growth [57][60] Question: Enrollment progress in the LUMINA study - Management reported that enrollment is gaining momentum, with U.S. centers expected to come online soon [62] Question: Revenue recognition for patients receiving only one dose - Management clarified that revenue recognition will depend on whether patients receive a second dose, with specific factors influencing the timing [63][64] Question: Potential for early data disclosure from ongoing studies - Management stated that they do not plan to disclose early data from studies like BOBCAT and LUMINA to maintain the integrity of the trials [71][73]

Financial Data and Key Metrics Changes - Total clinic revenue for the full year reached $1,163 million, representing a 2% year-over-year growth [2] - Average revenue per customer rebounded significantly in Q4, reaching $316, an 11% increase year-over-year [3] - Net income attributable to shareholders grew 9% year-over-year to $51 million, and EPS increased 4% to $0.50 [5] - EBITDA was $70 million with an EBITDA margin of 40.4%, indicating strong profitability [5] Business Line Data and Key Metrics Changes - The company operated 283 locations and served 6.63 million customers over the trailing 12 months [2] - Aesthetic dermatology accounted for 70% of the company's performance, while aesthetic surgery made up 30% [21] - The AGA hair loss treatment network has become one of the largest in Japan, with ongoing expansions in orthopedics and fertility treatment [9] Market Data and Key Metrics Changes - The aesthetic dermatology market in Japan is growing at nearly 10% annually, while aesthetic surgery is growing at about 3% [21] - The domestic medical expenditure in Japan is approximately JPY 48 trillion annually, presenting a significant market opportunity [17] Company Strategy and Development Direction - The core strategic pillars include aesthetic dermatology, non-aesthetic healthcare, and global expansion, with a focus on longevity and AI-driven healthcare [6][7] - The company aims to launch SBC Wellness 2.0, integrating biomarker analysis and AI-powered diagnostics to create a new category of performance medicine [7][8] - Plans for international expansion include strategic investments in the U.S. and partnerships in Asia, focusing on building a strong operating platform [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about recovery in customer spending and growth in aesthetic medicine, with expectations of continued strong performance [15][16] - The company aims to achieve a number one position in various medical fields in Japan by 2035, leveraging its strengths in aesthetic medicine [18][19] - AI is seen as a foundational pillar for growth and efficiency, with plans to enhance operational capabilities through AI technologies [11][26] Other Important Information - The company has a robust capital allocation policy prioritizing growth investments while maximizing shareholder value [12] - A share buyback program was approved, allowing for flexible repurchase of shares if market conditions are favorable [41] Q&A Session Summary Question: Current status of the healthcare and aesthetic medicine market in Japan - Aesthetic dermatology is growing by 10% annually, while aesthetic surgery is growing at 3% [21] Question: Will SBC Wellness be a growth driver in FY 2026? - SBC Wellness is not expected to be a large revenue driver initially; the focus is on expanding the customer base [22][23] Question: What operational improvements are expected from AI? - AI will enhance efficiency in headquarters and clinics, with a focus on creating success cases for future external sales [26][27] Question: What is the future M&A strategy? - The company aims to engage in M&A to achieve a number one position in various medical fields by 2035 [28][29] Question: Next steps for OrangeTwist investment? - The company plans to leverage its expertise in aesthetic medicine and explore entry into the longevity market with OrangeTwist [31][32] Question: Any plans for medical tourism? - Currently, there are no plans for medical tourism related to fertility treatment in Mexico, but opportunities may exist in Asia [36] Question: Comments on the company's cash position? - The company has abundant cash for safe investments and M&A opportunities, allowing for flexible use of funds [37][38]

Financial Data and Key Metrics Changes - Q4 2025 achieved record revenues of $13.4 million, a 30% increase compared to the same quarter last year, with Adjusted EBITDA rising to $4.8 million from $3.7 million, representing 36% of revenues [4][20] - Full year revenues reached $44.1 million, up 35% from 2024, with Adjusted EBITDA increasing to $13.6 million, an 89% rise from $7.2 million the previous year [4][20] - Gross margins expanded to 77%, driven by pricing improvements in consumables and reductions in system cost of revenue [20] Business Line Data and Key Metrics Changes - The company sold 624 UltraMIST systems in 2025, compared to 374 in the previous year, with Q4 sales of 255 systems marking the highest in company history [4][20] - The company discontinued the dermaPACE and Profile product lines in Q4, which impacted costs [5] Market Data and Key Metrics Changes - Changes in CMS reimbursement for skin substitutes have significantly affected the industry, with a 90%-95% price cut in a $15 billion category, leading to intense pressure on practitioners [6][7] - The company noted a reduction in customer count and patient count due to the reimbursement changes and audit pressures [8] Company Strategy and Development Direction - The company is focusing on expanding its active system base and engaging with new resellers to capitalize on market opportunities created by industry disruptions [11][12] - The strategy includes working with resellers who have strong customer relationships and expertise in wound care, aiming to increase market penetration [12][15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the current challenges in the wound care space but expressed optimism about future growth as new market opportunities arise [18][28] - The company anticipates a revenue growth range of 16%-25% for 2026, despite the initial impact of CMS changes [28] Other Important Information - The company restated financials due to previously unrecognized sales tax liabilities and revenue allocation errors, with a total revenue impact of approximately $300,000 [21] - Current assets totaled $24.6 million as of December 31, 2025, with cash and cash equivalents at $12 million [26] Q&A Session Summary Question: Can you speak about the selling cycle for inbound interests? - Management noted that the selling cycle has been stretched due to industry shock but is starting to improve [32][33] Question: What can we expect for Adjusted EBITDA in 2026? - Management refrained from providing specific guidance but indicated that incremental revenue would likely drop around 50% to the EBITDA line [34][35] Question: How should we think about growth rates after Q1? - Management expects the rest of the year to be better than Q1, but it is too early to break it down by quarter [38][40] Question: What does the commercial organization look like? - The internal sales force is being expanded, and the company is working with larger resellers that have significant personnel [42][43] Question: Can you provide updates on the manufacturing line for applicators? - Management reported delays in qualifying the new manufacturing line but is hopeful for progress in the coming months [56] Question: Why were 168 UltraMIST systems discontinued? - Discontinuations were primarily due to customers not ordering for six months or no longer operating their businesses [63][64] Question: Do customers tend to use UltraMIST consumables at a steady rate? - Usage rates vary significantly by customer type, with some ramping up quickly while others take longer [71][72]

Financial Data and Key Metrics Changes - Q4 2025 revenue increased by 32% compared to Q3 2025, approaching the revenue level of the prior year quarter despite a significantly reduced team [6] - Full year pro forma cash basis EBITDA improved by 31% compared to 2024, with a 56% improvement in Q4 alone [6] - Gross margin for the year improved to 40%, up from 38% in 2024 [7] - Net operating results for 2025 improved by 23%, while GAAP net loss for Q4 2025 was impacted by one-time accounting-related charges totaling $6.3 million [7] Business Line Data and Key Metrics Changes - The revenue mix has diversified, reducing reliance on a single platform, with revenue now more balanced across Roblox, Minecraft, Fortnite, and mobile playable ads [8] - Mobile playables accounted for over 25% of revenue in Q4 2025, ending the year at about 20% [32] - Revenue from Roblox diminished to under 40% of total revenue, while Fortnite and Minecraft collectively contributed about 30% [32] Market Data and Key Metrics Changes - The U.S. digital advertising market is valued at $316 billion, with a gaming population of 200 million, yet total yearly spend in gaming remains under $10 billion [9][10] - Consumers spend approximately 11.8 hours per week playing video games, nearly equal to time spent on social media and streaming [9] Company Strategy and Development Direction - The company aims to maintain a lower cost structure while expanding scalable, repeatable revenue streams [14] - The acquisition of the Misfits Ads Division is expected to enhance revenue capabilities and contribute significantly to cash basis EBITDA profitability [11][21] - The focus is on integrating the Misfits Ads Division and leveraging its technology and partnerships to drive growth [45] Management's Comments on Operating Environment and Future Outlook - Management expects Q1 2026 revenue to exceed Q1 2025, with a consistent pipeline and average deal size above $200K [12] - The full financial impact of recent changes is not yet reflected in reported results, with more meaningful progress anticipated in Q2 2026 [12] - Confidence in achieving cash basis EBITDA profitability by year-end 2026 is based on the completion of restructuring and a stronger revenue pipeline [18] Other Important Information - The company has a debt-free balance sheet with over $14 million in capital as of December 31, 2025 [4] - The strategic focus includes evaluating opportunities related to digital assets while remaining optimistic about long-term potential [13][14] Q&A Session Summary Question: Progression towards cash-based EBITDA profitability in 2026 - Management outlined a three-phase approach for 2026, with Q1 showing lag from restructuring, Q2 expected to show inflection, and the second half focused on delivery [16][17] Question: Details on the Misfits acquisition and its impact - The acquisition is expected to consolidate complementary businesses and provide access to a profitable revenue stream, potentially contributing 50% of 2025 net revenue [19][21] Question: Sustainability of gross margin improvements - Management anticipates maintaining gross margins in the 40%-45% range, with hopes to achieve closer to 45% for the full year [24][25]

Financial Data and Key Metrics Changes - Net sales for 2025 totaled $118.4 million, a 7.6% decrease from $128.1 million in 2024 [10] - Net sales for Q4 2025 were $3.3 million, a 5.9% increase from $28.6 million in Q4 2024 [10] - Gross margin percentage increased to 15.2% in 2025 from 13.1% in 2024 [13] - Adjusted EBITDA for Q4 2025 was $1.2 million, compared to a loss of $889,000 in Q4 2024 [19] - Cash totaled $1.7 million as of December 31, 2025, up from $916,000 a year earlier [15] Business Line Data and Key Metrics Changes - Medical imaging net sales increased by $2.5 million or 6.7% in 2025 compared to 2024 [10] - Medical device net sales decreased by $184,000 in Q4 2025 compared to Q4 2024 [11] - Aerospace and Defense net sales decreased by $5 million in 2025 but increased by $1.1 million in Q4 2025 compared to the same quarter in 2024 [12] - Industrial net sales decreased by $4.6 million or 12.9% for the full year and by $607,000 or 7.7% in Q4 2025 compared to Q4 2024 [12][13] Market Data and Key Metrics Changes - Customer backlog increased to $77.3 million at year-end 2025, a 17.4% increase from $65.9 million at the end of 2024 [4][13] - The company is seeing strong quoting activity as customers evaluate nearshore manufacturing strategies [7] Company Strategy and Development Direction - The company is focused on strengthening its balance sheet and reducing inventory investments in 2026 [20] - There is an emphasis on driving efficiencies in manufacturing processes and improving free cash flow [21] - The company is investing in new technologies and regulatory capabilities to leverage future growth [27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about positioning in the nearshoring landscape and the benefits of increased backlog [27] - The company is monitoring trade policies and geopolitical uncertainties closely [8] - Management believes they have overcome revenue and earnings headwinds and are optimistic about 2026 [20] Other Important Information - The company entered into new agreements for a $2.2 million term note and a $15 million asset-backed line of credit [6] - The restructuring activities in 2024 and early 2025 are yielding positive operational and financial results [27] Q&A Session Summary - No questions were asked during the Q&A session, and the call concluded without any inquiries from participants [29][30]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $8.4 million, down from $14.6 million in Q4 2024, primarily due to government shutdown impacts [25] - Product revenues decreased to $5.6 million from $12.6 million year-over-year, attributed to delays in product orders and shipments for U.S. Defense applications [25] - Non-product revenues increased to $2.5 million from $1.7 million, driven by the IVAS color MicroLED development program [26] - Cost of product revenue was $4.7 million, representing 83% of net product revenues, compared to $10.7 million or 84% in the previous year [27] Business Line Data and Key Metrics Changes - The defense programs remain the core of the business and the strongest growth driver, with ongoing supply for thermal weapon sight programs [12] - The company has seen increased demand for its products due to geopolitical tensions, particularly in defense applications [5] - The partnership with Theon International is expected to significantly contribute to revenue growth, especially in European markets [10] Market Data and Key Metrics Changes - Increased defense budgets across NATO member states are driving growth expectations, particularly in Europe [10] - The U.S. Army's intent to procure over 1 million drones is expected to accelerate demand for the company's display and optical technologies [11] - The first-person drone market is projected to grow from under $300 million to $1.2 billion by 2030, indicating a 31% compound annual growth rate [11] Company Strategy and Development Direction - The company is transitioning from a legacy microdisplay company to a vertically integrated advanced technology platform [5] - The second phase of the transformation plan focuses on accelerating revenue growth, expanding customer reach, and innovating product offerings [21] - The company aims to execute on defense programs, grow revenues from the Theon partnership, and advance MicroLED technology towards production [22] Management's Comments on Operating Environment and Future Outlook - The government shutdown is viewed as a temporary setback rather than a long-term issue, with confidence in the recovery of revenue as government operations normalize [22] - The company is optimistic about its strategic positioning and strong pipeline, providing conservative revenue guidance of $52 million to $60 million for 2026 [22] - Management expresses excitement about the company's transformation and growth potential, emphasizing the unique competitive advantage of being the only manufacturer of four types of microdisplays [31] Other Important Information - The company raised $56 million in capital from strategic and institutional investors, strengthening its balance sheet [4] - The deconsolidation of the U.K. entity in Q4 was noted, but it is expected to be temporary [23] - The company is actively engaged with government agencies to secure additional funding and contracts [54] Q&A Session Summary Question: What is the backlog as of December 31 and remaining performance obligations? - Backlogs were approximately $37 million, with expectations to book larger orders soon [38] Question: Will the MicroLED program development extend into 2027? - The company is working towards completion this year, with technical milestones on track [41] Question: How should capacity needs be considered for the SBMC program? - The company has selected tooling equipment for production and does not require further CapEx to meet current program demands [45] Question: When will the $1 million in annualized savings from automation be achieved? - Savings are already being realized and will be reflected in OpEx this year [47] Question: What is the outlook for the commercial open-market opportunity in the U.S. for drones? - There is surging demand for first-person viewers and related technologies due to the FCC's DJI ban [51] Question: How much might be allocated for microdisplays and optics from the $450 billion reconciliation bill? - The company is actively seeking additional funding and expects positive outcomes from ongoing discussions [54] Question: Are there new markets and technologies outside the defense industry? - The company plans to announce two new products in new markets this year, which are currently under development [59]